17 Nov 2026, Tue

I’ve been waiting DECADES for this…

A note from our friends at The Oxford Club(ad)

Editor’s Note: Over the past 20 years, Matt McCall has written up 50 stocks before they soared tenfold or more. Today he’s giving away a favorite new pick, free… at the center of what Dr. Mark Skousen calls “the most dangerous boom in history.” Click here to get the full details or read more below.


Dear Reader,

I recently sat down with Dr. Mark Skousen…

And he told me something that contradicts just about EVERYTHING we’ve been hearing about the stock market.

In short…

He says an astounding amount of money could flood into the markets in the years ahead.

We’re talking $60 trillion in new wealth up for grabs between now and 2029.

In my career, I’ve found 50 stocks before they soared tenfold or more.

(Most investors are lucky to see one ten-bagger in their lifetime.)

And I can tell you flat out…

I’ve never been more excited for what’s coming than I am right now.

See why here!

And as a special thank you for watching, you’ll get one of my favorite picks.

If you buy just one stock for the rest of the year, I urge you to make it this one. (I can almost guarantee you’ve never heard of it.)

Regards,

Matt McCall
Editor, McCall’s Innovation Report

 
 
 
Bonus Article

Why Daily Gold Alerts Is Not Covering the Lilly Deal

Eli Lilly’s agreement on Monday to acquire Calytrix Bio for up to $1.5 billion is a significant piece of pharmaceutical news. Calytrix, a Wellesley Hills, Massachusetts biotech founded in 2025, is developing an investigational biparatopic antibody targeting myeloproliferative neoplasms, specifically essential thrombocythemia and myelofibrosis. These are real numbers, and the M&A pace is genuinely remarkable.

But this is not the story for Daily Gold Alerts, and explaining why is worth a moment of your time.

This publication exists to answer one question every morning: what is the most important development in precious metals today, and how should investors think about it? Gold prices, silver industrial demand, central bank reserve policy, mining economics, real interest rates, the dollar, royalty company cash flows. That is the remit. When a story falls outside it, the right call is to say so rather than force a connection that does not exist.

The Lilly-Calytrix deal has no meaningful link to gold, silver, platinum, palladium, or the companies and macro forces that drive them. Lilly is a pharmaceutical giant looking to expand its oncology pipeline beyond its blockbuster diabetes and obesity franchise. That is a legitimate corporate strategy story. It belongs in a healthcare publication, a biotech letter, or a broad equity service. It does not belong here, and dressing it up with a tenuous macro hook would waste your time and compromise the analytical standard this publication is built on.

The contrast with assets that do belong in this publication is instructive. Central banks spent August buying gold while ETF flows chased Bitcoin, and the divergence in those demand bases tells the real hard-money story.

Editorial discipline is not a constraint. It is what makes the analysis useful. A publication that covers everything covers nothing well. The precious metals market is deep enough, complex enough, and consequential enough to deserve focused, rigorous attention every single day.

The forces worth watching right now are real. Dollar strength, Federal Reserve rate expectations heading into year-end, central bank gold purchase data from the World Gold Council, and silver’s industrial demand profile as manufacturing PMIs shift across Asia. Any one of those threads, examined carefully, tells investors something they can act on. A pharmaceutical acquisition tells them nothing about their gold portfolio.

So today’s issue will not cover Lilly. When the most important precious metals development of the day is clear, you will read about it here with the full weight of analysis it deserves. That is the commitment this publication makes, every morning, without exception.